Hormonal
Once-weekly subcutaneous semaglutide at 2.4mg induces significant weight loss (mean 14.9%) in adults with obesity, significantly outperforming placebo.
For adults with obesity, once-weekly subcutaneous semaglutide at 2.4mg is a highly effective treatment for weight loss, averaging a 14.9% reduction in body weight over 68 weeks when combined with lifestyle changes. This is significantly better than placebo. Patients should expect potential gastrointestinal side effects, which are usually temporary, and adhere to the titration schedule to minimize them.
Semaglutide-treated subjects achieved a mean weight loss of 14.9%, (from baseline body weight of 105.3 kg) compared to a 2.4% weight loss with placebo; 86.4% achieved weight loss > 5% compared to 31.5% with placebo.
Why this rating
Based on Phase 3 RCT (STEP 1) with 1,961 participants, meeting co-primary endpoints with high statistical significance.
Source
Recent developments in <scp>GLP‐1RA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie Bain et al. · Diabetes Obesity and Metabolism · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →